COAG

Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029, supporting multiple clinical catalysts across sutacimig, HMB-002, and preclinical HMB-003. Lead asset sutacimig shows strong Phase 2 efficacy and FDA-aligned Phase 3 dosing, while HMB-002 and HMB-003 broaden addressable markets.

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underway

Hemab Therapeutics NASDAQ: COAG Chief Executive Officer Benny Sorensen outlined the company's development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were sold by Hemab. Hemab's common stock began trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, were approximately $346.7 million.